Literature DB >> 10701398

[Primary epiploic appendicitis: CT diagnosis for conservative treatment].

M Boudiaf1, S H Zidi, P Soyer, Z Hamidou, Y Panis, J P Pelage, R Rymer.   

Abstract

OBJECTIVE: Primary epiploic appendicitis is an uncommon, self-limited disease with spontaneous resolution. Diagnosis is usually made at surgery as the disease is generally mistaken for acute appendicitis or sigmoid diverticulitis. CT allows a non-invasive diagnosis, thus avoiding unnecessary surgery. The condition can be managed conservatively with the use of analgesic drugs only, and clinical evolution is uneventful. The aim of this study is to report the CT features of this pathologic process before and after medical treatment by analgesics. PATIENTS AND
METHOD: Six patients (4 men and 2 women aged from 23 to 70 year old mean; 29 year old) underwent abdominal CT scan because of acute abdominal pain located in the left lower quadrant (n = 3) and right lower quadrant (n = 3). No patient had fever. Laboratory findings were normal in all cases. Follow-up CT scans were obtained in 4 patients respectively at 2, 4, 8 and 80 weeks.
RESULTS: CT scan showed in all cases a fatty mass located to the anterolateral wall of the colon, delineated by an hyper attenuating rim. Infiltration of the pericolic fat was noted in all cases. Follow up CT scans obtained in 4 patients showed that the inflammatory signs had cleared in all cases, the lesion had disappeared (n = 2), decreased in size (n = 1) or a residual paracolic node was observed (n = 1).
CONCLUSION: Primary epiploic appendicitis is a rare disease. Knowledge of CT signs allowed the correct diagnosis and a conservative management.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10701398

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  1 in total

1.  Epiploic appendicitis in inguinal hernia sac presenting an inguinal mass.

Authors:  H Kulacoglu; H Tumer; R Aktimur; A Kusdemir
Journal:  Hernia       Date:  2005-10-22       Impact factor: 4.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.